To include your compound in the COVID-19 Resource Center, submit it here.

Treadwell emerges with two clinical cancer compounds, $27M seed from Tio

Cancer play Treadwell debuted Monday as Tio Bioventures’s first portfolio company with $27 million in seed funding and a pair of differentiated oral small molecules that are already in the clinic.

Founded last year, Tio intends to invest its $120 million first fund in three to five internally incubated companies, with a primary focus on first-in-class therapies discovered

Read the full 572 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers